Eplontersen Fails Phase 3 in ATTR-CM: IONS, AZN Hit

Ionis Pharmaceuticals (IONS) and partner AstraZeneca (AZN) announced on July 9, 2026, that the Phase 3 CARDIO-TTRansform trial of eplontersen (Wainua) in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet its primary endpoint. The composite of cardiovascular mortality and recurrent cardiovascular clinical events through Week 140 showed no statistically significant benefit over placebo.

IONS closed at $56.55 on July 23, with a market cap of approximately $9.2 billion. The stock had already absorbed the news, which broke more than two weeks earlier. Wolfe Research downgraded Ionis from Outperform to Peer Perform the day after the announcement, and Guggenheim lowered its price target from $106 to $89.

The largest ATTR-CM trial ever

CARDIO-TTRansform enrolled 1,432 patients across 130 sites in 20 countries, making it the largest ATTR-CM study conducted. The Ionis press release confirmed the primary endpoint miss and highlighted a pre-specified subgroup finding: eplontersen monotherapy showed nominally significant benefit in patients not on background TTR stabilizers, while no treatment effect was observed in patients already on stabilizer therapy at baseline.

That subgroup result matters for the regulatory path forward. Roughly 57% of patients were on TTR stabilizers at baseline, and another 24% initiated them during the trial. The add-on design may have diluted the treatment effect, making it impossible to show incremental benefit on top of existing standard of care.

Why this hurts

Eplontersen is already FDA-approved for ATTR polyneuropathy (Wainua, 2025). A label expansion into ATTR-CM would have significantly expanded the commercial opportunity, since cardiomyopathy is far more common than polyneuropathy. ATTR-CM affects an estimated 300,000 to 500,000 people worldwide, an underrecognized cause of progressive heart failure caused by amyloid protein deposits stiffening the heart muscle.

The failure is a setback for the RNA-targeted therapy field. Eplontersen is a ligand-conjugated antisense oligonucleotide (LICA) that silences transthyretin production at the source. The mechanism works in polyneuropathy, but the cardiomyopathy trial suggests that silencing TTR production may not add meaningful benefit when patients are already taking TTR stabilizers like tafamidis.

The competitive context

Pfizer’s Vyndaqel and Vyndamax (tafamidis) are the standard of care for ATTR-CM, having demonstrated cardiovascular benefit in the landmark ATTR-ACT trial. BridgeBio’s acoramidis was also recently approved. Eplontersen would have been an add-on or alternative in this space, but the CARDIO-TTRansform failure leaves the combination question unresolved.

For a framework on interpreting clinical trial failures and what they mean for drug pipelines, see our guide to reading a clinical trial press release.

What to watch next

Full data will be presented at ESC 2026 (European Society of Cardiology Congress). The monotherapy subgroup signal could support a targeted regulatory filing in stabilizer-naive patients, though Ionis and AstraZeneca have not confirmed that strategy. The key risk for Ionis investors is whether the company can still build a meaningful cardiovascular franchise from eplontersen, or whether the asset is now limited to the smaller polyneuropathy indication.

Ionis has a deep pipeline of RNA-targeted therapies beyond eplontersen, including eplontersen’s successor programs. But this was the key near-term cardiovascular catalyst, and it failed. The stock at $56.55 reflects a company whose pipeline value now depends on readouts further out.

Source: Ionis press release | AJMC coverage